Quanterix 2025 Q2 Earnings Deepened Losses Despite Strategic Progress

Quanterix(QTRX) reported its fiscal 2025 Q2 earnings on Aug 07th, 2025. The company delivered results that significantly missed expectations, with a widening net loss and a steep revenue decline. The firm guided for full-year 2025 revenue of $130–$135 million and outlined its path toward cash flow breakeven in 2026.

Quanterix reported a 28.8% drop in total revenue to $24.48 million in 2025 Q2, compared to $34.38 million in the same period the previous year. The decline was observed across all major revenue streams, reflecting ongoing market challenges and integration impacts. The company generated $16.83 million from product sales, supported by $7.09 million in service and other revenue. Collaboration and licensing revenue contributed $532,000, while grant revenue accounted for a modest $22,000. Collectively, these figures highlight a broad-based slowdown in revenue performance.

Quanterix’s losses deepened significantly, with a net loss of $30.01 million, or $0.77 per share, representing a 306.3% increase from the $7.39 million loss, or $0.19 per share, in 2024 Q2. The company has now recorded losses for nine consecutive years during this fiscal quarter, underscoring persistent financial pressure despite strategic initiatives. This worsening profitability raises questions about the company’s ability to achieve profitability in the near term.

The stock price of Quanterix has continued to decline across multiple time frames, with a 2.99% drop on the most recent trading day, a 7.24% decline for the week, and a sharp 15.75% drop month-to-date. Investors have clearly reacted negatively to the earnings results and the broader outlook.

An analysis of post-earnings performance revealed mixed returns for strategies tied to Quanterix. The strategy of buying shares after a quarter-over-quarter revenue increase and holding for 30 days generated a 23.19% return over the past three years—moderate but significantly underperforming the benchmark’s 22.44%. The Sharpe ratio of 0.69 suggested reasonable risk-adjusted returns, but the compound annual growth rate of just 18.22% indicated a conservative growth trajectory.

Masoud Toloue, CEO of Quanterix, emphasized the long-term potential of the business following the merger with Akoya Biosciences, calling it a high-margin, high-throughput opportunity in an expanded market. Despite near-term challenges, particularly in the US academic sector, the company saw significant progress in its Alzheimer’s Diagnostics segment, which tripled year-over-year. Toloue also highlighted the growth in the Accelerator business, noting a net increase in new customers. Additionally, the company has achieved 75% of its $85 million synergy and cost reduction target, and remains on track to reach cash flow breakeven by 2026.

Quanterix expects full-year 2025 revenues in a range of $130 to $135 million, which includes approximately two quarters of Akoya performance. On a pro forma basis, the company anticipates revenue of $165 to $170 million. The company forecasts GAAP gross margins of 49% to 53%, and adjusted gross margins of 45% to 49%. Quanterix also anticipates adjusted cash usage of $34 to $38 million for 2025, with an expected exit cash position of approximately $120 million.

Additional News

Nigeria’s Abuja Technology Village Free Zone remains under review amid a potential revocation of its free zone status. The Nigeria Export Processing Zones Authority has intervened in the dispute with the Federal Capital Territory Administration, signaling heightened regulatory scrutiny for the technology-focused hub. Meanwhile, the Africa CDC reported a 58% decline in mpox cases across the continent, offering some optimism amid ongoing public health challenges. U.S.-Nigeria relations saw developments as the U.S. envoy and Nigerian minister addressed recent visa policy changes, urging compliance with new regulations. Additionally, the U.S. gold futures market hit a record high following reports of tariffs on bullion bars, reflecting global economic uncertainty and volatility in precious metals.